Every biotech seeking a suitor wants to know: What does it take to charm a Big Pharma into a deal?
To answer this question, deal-makers from five pharma giants shared a stage at Fierce Biotech's London Life Sciences Week event in London on Tuesday to offer insight into their indvidual approaches.
Juergen Eckhardt, M.D., head of business development and licensing for Bayer's pharmaceuticals division, warned biotech executives in the audience not to come at companies with an aggressive sales pitch.
“There may be a temptation to spam a Big Pharma company that you find on LinkedIn,” said Eckhardt, who is also head of Leaps by Bayer. But this approach is “not usually a good strategy, because we all have our own processes and how we work through these opportunities that present themselves.”
When companies are too aggressive with a sales approach, it can damage trust at the start of the relationship. “Be more patient,” advised Eckhardt.
“At the end of the day, what we're looking for is great science and, of course, great data,” he added. “That’s what will make the difference.”
Tim Egan, head of search and evaluation, business development at GSK, echoed this point and emphasized the need for biotechs to be upfront about what data they have to hand.
“Transparency is what we look for,” Egan said, when asked by Fierce Biotech Senior Editor James Waldron about red flags for a deal. “And by that, I mean no data curation and just as much candour as possible. The reality is that every program, every asset, is going to have its worth, but don’t hide any bad parts.”
“I think that really sets the tone for how we work together as partners,” Egan added. “Give us the unblemished or the full-blemished data set, and we'll make a judgment about whether it's a good scientific fit.”
Biotechs that try to mask these “blemishes” will simply be unearthed anyway, he pointed out. “I think that can set a really bad tone if we get the impression that something's being withheld that is material to the case.”
Arguably the most prolific deal-maker of 2026 has been Eli Lilly, which announced a $1.5 billion acquisition on Monday of myelofibrosis biotech Calytrix Bio and then followed this up with a $5.9 billion oncology pact with Stipple Bio on Tuesday.
Speaking on the same panel, Rachel Zolot Schwartz, VP of corporate development and BD strategy at the Indianapolis drugmaker, said her company is “in the fortunate position to share risk with our partners.”
“We'd like to share in that risk and find ways to add capabilities,” she continued. “That could be in areas such as a broader development plan, or within the realms of manufacturing. We all bring capital, but we're doing deals where we can really add capabilities.”
Grace Han McMahon, who leads Pacific business development and licensing for Merck & Co., pointed out that “deal structure comes first.”
“It's the scientific diligence, and it's important that companies allow a potential partner full diligence for not only their lead assets or their technology or platform, but also their capabilities,” she explained.
When asked how much patent cliffs factor into dealmaking, the panel was clear: Big drugs losing their protection is rarely the key factor in driving teams to find deals.
Nauman Shah, global head of innovative medicine business development at Johnson & Johnson, said his company had already been through one major patent cliff with the exclusivity loss of its immunology blockbuster Stelara last year.
“We grew through that,” said Shah—no mean feat for a $10 billion product.
“So, we have that performance as we go forward,” he added. “I think that's ultimately the approach: to be proactive in looking for outstanding additions to our portfolio, continuing to invest heavily in R&D internally, and complementing it with robust external innovations.”
“Yes, there are going to be patents that expire at some point,” Shah said. “But at the end of the day, I think we're in a really nice position with the robust R&D pipeline that we have, with the portfolio that we have in market, and then obviously complementing it to accentuate it with business development even further.”
J&J had its own acquisition to celebrate earlier this week, courtesy of a $2.2 billion payout to buy Ollin Biosciences for its potential rival to Roche’s blockbuster eye disease drug Vabysmo.
Shah added that J&J will continue to seek external deals “on the basis of opportunity [and] where the science is absolutely outstanding, whether that's new science that we're adding or something better than what we had internally and ultimately, of course, with the goal of solving important patient unmet need.”